Related Experiment Video
Updated: Jul 16, 2025
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.4K
Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer
Feng Liu1, James D Ververs1, Michael K Farris1
1Department of Radiation Oncology, Wake Forest University School of Medicine and Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
International Journal of Radiation Oncology, Biology, Physics
|September 21, 2023
Summary
This study validates radiobiological models for non-small cell lung cancer (NSCLC) radiation therapy, finding optimal fractionation regimens independent of specific models. These findings support safe and effective SBRT and hypofractionated treatments for maximal tumor control.
Area of Science:
- Radiation Oncology
- Medical Physics
- Clinical Oncology
Background:
- Stereotactic Body Radiation Therapy (SBRT) and hypofractionated radiation therapy are increasingly used for early-stage non-small cell lung cancer (NSCLC).
- Accurate radiobiological modeling is crucial for optimizing treatment efficacy and minimizing toxicity.
- The Hypofractionated Treatment Effects in the Clinic (HyTEC) working group developed models to predict tumor control probability (TCP).
Purpose of the Study:
- To validate existing radiobiological models using an expanded dataset of clinical TCP data for early-stage NSCLC.
- To determine model-independent optimal fractionation regimens for radiation therapy of early-stage NSCLC across a range of 1 to 30 fractions.
- To assess the performance of HyTEC models with recent clinical data encompassing conventional and SBRT fractionation.
Main Methods:
- Collected and analyzed actuarial or Kaplan-Meier TCP data from 9808 patients across 56 published studies.
- Utilized data for conventional radiation therapy (2-4 Gy/fraction) and SBRT for early-stage NSCLC.
- Validated HyTEC model parameters against this expanded clinical dataset.
Main Results:
- The HyTEC models, with an alpha/beta ratio of approximately 20 Gy, accurately describe the expanded clinical TCP data.
- A sharp increase in TCP with biologically effective dose was observed, reaching a plateau.
- Optimal fractionation schemes were determined, showing that T2 tumors require slightly higher doses than T1 tumors.
Conclusions:
- The validated HyTEC models effectively describe TCP data for both conventional and SBRT fractionation in early-stage NSCLC.
- The steep dose-response and asymptotic TCP plateau enable the determination of model-independent optimal fractionation regimens.
- Proposed optimal fractionation schemes align with current clinical practices for SBRT in early-stage NSCLC, aiming for maximal tumor control.
